

UNITED STATE EPARTMENT OF COMMERCE Patent and Trademark Office

DATE MAILED:

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

			ATES O	washingtor	1, 0.0. 20201	K
	APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
	09/445,205	01/07/00	GALZI		Ţ.	97AHCNRFLU
	_		7		EXAMINER	
	000466 YOUNG & THOMPSON 745 SOUTH 23RD STREET		HM12/1003		SISSC	IN. B
			2ND FLOOR		ART UNIT	
	ARLINGTON V				1655	φ

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

10/03/00

1- File Copy

	Application No.	Applicant(s)							
	09/445,205	GALZI ET AL.							
Office Action Summary	Examiner	Art Unit							
	Bradley L. Sisson	1655							
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>1</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.									
 Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). 									
1) Responsive to communication(s) filed on									
2a) ☐ This action is FINAL. 2b) ☑ Th	is action is non-fin	al.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Disposition of Claims									
4)⊠ Claim(s) <u>1-34</u> is/are pending in the application.									
4a) Of the above claim(s) is/are withdrawn from consideration.									
5) Claim(s) is/are allowed.									
6) Claim(s) is/are rejected.									
7) Claim(s) is/are objected to.									
8) Claims 1-34 are subject to restriction and/or election requirement.									
Application Papers									
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are objected to by the Examiner.									
11) The proposed drawing correction filed on is: a) approved b) disapproved.									
12) The oath or declaration is objected to by the Examiner.									
Drianity, under 25 H.C.C. \$ 449									
Priority under 35 U.S.C. § 119									
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) ☐ All b) ☐ Some * c)⊠ None of the CERTIFIED copies of the priority documents have been:									
a) ☐ All b) ☐ Some * c) ☑ Notice of the CERTIFIED copies of the phonty documents have been. 1. ☐ received.									
2. received in Application No. (Series Code / Serial Number)									
3. received in Application No. (Genes Code / Centar Nambol)									
* See the attached detailed Office action for a list of the certified copies not received.									
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).									
· · · · · · · · · · · · · · · · · · ·									
Attachment(s)	40.	Interview Cummery (PTO 442) Ben-	er No(s)						
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	18) 19)) 20) 🔀	Interview Summary (PTO-413) Pape Notice of Informal Patent Application Other: Notice to Comply with Seque	n (PTO-152)						

Application/Control Number: 09/445,205

Art Unit: 1655

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9 and 22-26, drawn to use of a fluorescent protein.

Group II, claim(s) 10-21 and 27-28, drawn to process for detecting and quantifying non-covalent interactions between the target protein and one of its ligands.

Group III, claim(s) 29-31, drawn to cells or fragments of cells containing a DNA sequence comprising the gene coding for a fluorescent protein fused with the gene for a target protein.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The use of modified GFP from jellyfish as a marker or label for the expression of other proteins was known prior to the filing of the earliest priority document; see WO 96/27675. While the claims are linked by GFP, GFP does not constitute a special technical feature. Accordingly, the claims are not linked by a special technical feature and restriction is therefore.

2. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/445,205

Art Unit: 1655

Sequence Rules Compliance

3. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (703) 308-3978. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 308-0294 for After Final communications.

Application/Control Number: 09/445,205

Art Unit: 1655

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

> Bradley L. Sisson Primary Examiner Art Unit 1655

BLS September 29, 2000